RALEIGH, N.C., Jan. 9 /PRNewswire/ -- Qualyst today announced that InterMune, Inc., a biotechnology company with a pipeline portfolio addressing idiopathic pulmonary fibrosis and hepatitis C infections, has signed a multi- year license to use Qualyst’s proprietary, patented B-CLEAR(R) system for its drug discovery programs. Terms were not disclosed.
B-CLEAR(R) is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance and drug transport. B-CLEAR(R) offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges, and enabling better prediction of bioavailability, pharmacokinetics, species- specific drug dosing and candidate selection.
“As knowledge of the critical nature of drug transporters increases, companies that use B-CLEAR(R) are able gain a competitive advantage by acting on observed transport-related properties of their therapeutic leads,” stated Scott Neuville, Qualyst president and CEO.”
About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualyst’s products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company’s web site at www.Qualyst.com or call 919-313-6500.
Qualyst, Inc.
CONTACT: Ian J. Mehr, Vice President, Business Development, of Qualyst,Inc., +1-919-313-6507, or info@qualyst.com
Web site: http://www.qualyst.com//
